




Bismuth compounds and cancer

Bismuth compounds: pro-drugs




Bismuth compounds and cancer

Bismuth compounds: pro-drugs

H.p. causative agent for gastrointestinal cancers

WHO: class 1 carcinogen




Bismuth compounds and cancer


Bismuth compounds: pro-drugs


H.p. causative agent for gastrointestinal cancers


WHO: class 1 carcinogen


Combine bismuth with 'useful' thiols

















































Four to five weeks

Male and Female

Controls – 20 day max.

via intraperitoneal injection (i.p.)





Maximum Tolerated Dose - Balb/C mice

 $Bi(S_2CNEt_2)_3$: 7 mg Bi / kg

 $Bi(S_2CNBu_2)_3$: > 50 mg Bi / kg

Oral administration

 $Bi(S_2CNEt_2)_3$: ~ 50 mg Bi / kg



MTD - Balb/C mice - Ovcar: Ovarian cancer MTD = 7 mg Bi / kg ID₅₀ = < 3.2 ng Bi / kg "Therapeutic index" => 2.2 × 106

